Clinical trials: SCHIZOPHRENIA 1 (Disorder)
SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning
Simulation-Based Schizophrenia Training in Nursing Education
This study aims to examine the effect of a schizophrenia scenario-based simulation on nursing students' knowledge, empathy, and caregiving competence. The study uses a single-group pre-test/post-test (quasi-experimental) design.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning, Nursing Students
- Trial name
- NCT07757750
- Testing
- Simulation
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Medipol University
Clinical High Risk, Early Psychosis
Digital Strategies to Advance Help-Seeking Aim 1 and 2
This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis.
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Trial name
- NCT06774430
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Columbia University
Cognitive Function 1, Social
Social Cognition Assessment in Young Adults
The primary objective of this study is to determine the efficacy and feasibility of a battery of neuropsychological measures evaluating social cognition and behavior in young adults diagnosed with schizophrenia, autism spectrum…
- Trial name
- NCT02922400
- Testing
- Social Cognition Assessment and Training
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Bipolar 1 Disorder, Schizophrenia Disorder
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
- Trial name
- NCT07744113
- Testing
- OLZ/SAM
- Where
- United States
- Sponsor
- Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Trial name
- PAFIP3_1Y (NCT02532491)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
Agranulocytosis, Neutropenia
Time Course of Clozapine-associated Agranulocytosis Over 19 Years
Clozapine is the most effective antipsychotic medication for treatment-resistant schizophrenia, but it carries a rare, potentially life-threatening risk of agranulocytosis (a severe drop in white blood cells), which is why…
- Conditions
- Agranulocytosis, Neutropenia, SCHIZOPHRENIA 1 (Disorder), Treatment-resistant Schizophrenia
- Trial name
- NCT07913529
- Where
- Israel
- Volunteers
- 2,020 people
- Sponsor
- Sheba Medical Center
Schizophrenia, Autism
Lurasidone Pediatric Pharmacokinetics Study
This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric…
- Trial name
- NCT01620060
- Testing
- Lurasidone
- Where
- 10 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Mental Health Wellness 1
Evaluation of A Mindfulness Resiliency Training Program for Refugees Living in Jordan
To estimate the efficacy of a structured, scalable and replicable psychosocial intervention targeting refugees living in Jordan, Amman who have been forced to flee their homes due to regional conflicts.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Mental Health Wellness 1, War-Related Trauma
- Trial name
- NCT03760627
- Testing
- Refugees Mindfulness Resiliency Training, Mindfulness Resiliency Training
- Where
- Jordan
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Yale University
Auditory Hallucination, Hearing Voices When No One is Talking
Imagery Interventions for Auditory Vocal Hallucinations
This study explores the feasibility, acceptability, and effectiveness of four imagery intervention techniques (metacognitive imagery intervention, imagery rescripting, promoting positive imagery and competing imagery task) for…
- Conditions
- Auditory Hallucination, Hearing Voices When No One is Talking, Psychosis
- Trial name
- NCT05603260
- Testing
- Imagery intervention for voice hearing (meta-cognitive imagery rescripting), Imagery intervention for voice hearing (Imagery rescripting), Imagery intervention for voice hearing (promoting positive imagery de novo)
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Hella Janssen
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Prospective Studies of the Pathogenesis of Schizophrenia
The purpose of this study is to use structural and functional magnetic resonance imaging (MRI) to study children at high risk for schizophrenia.
- Trial name
- NCT00877552
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
SCHIZOPHRENIA 1 (Disorder)
Multi-target TMS for Schizophrenia Negative Symptoms
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left…
- Trial name
- NCT07559084
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.
- Trial name
- NCT02411695
- Testing
- Brexpiprazole (OPC-34712)
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD), SCHIZOPHRENIA 1 (Disorder)
Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders
The goal of this clinical trial is to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in reducing core symptoms of different psychiatric disorders using validated clinical scales.
- Conditions
- Major Depressive Disorder (MDD), SCHIZOPHRENIA 1 (Disorder), Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
- Trial name
- Transcranial (NCT07452835)
- Testing
- tDCS Parameters
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Menoufia University
Schizophrenia
A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Schizophrenia (SCH) is a devastating brain disorder with grave personal, family and social cost. SCH is a complex and heterogeneous (both genetic and clinical) disorder with oligogenetic endowed vulnerability risk of disease…
- Trial name
- SONPOS (NCT01075373)
- Where
- Taiwan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim